-
The Beauty Health Company (SKIN) Misses Q3 EPS by 2c
-
Canaccord Genuity Reiterates Hold Rating on The Beauty Health Company (SKIN)
-
The Beauty Health Company (SKIN) PT Raised to $2.50 at TD Cowen
-
Roth/MKM Starts The Beauty Health Company (SKIN) at Buy
-
The Beauty Health Company (SKIN) PT Raised to $2 at Jefferies, 'Tariff exposure should decline with the completed transition to a disty model in China'
-
The Beauty Health Company (SKIN) Tops Q2 EPS by 9c
-
The Beauty Health Company (SKIN) Announces Convertible Debt Refinancing
-
The Beauty Health Company (SKIN) PT Raised to $2 at TD Cowen
-
The Beauty Health Company (SKIN) Tops Q1 EPS by 5c
-
Grabar Law Office Investigates Claims on Behalf of Shareholders of the Beauty Health Company (SKIN)
-
Benchmark Reiterates Hold Rating on The Beauty Health Company (SKIN)
-
Stifel Reiterates Hold Rating on The Beauty Health Company (SKIN)
-
The Beauty Health Company (SKIN) PT Lowered to $1.50 at Canaccord Genuity
-
The Beauty Health Company (SKIN) Tops Q4 EPS by 3c
-
The Beauty Health Company (SKIN) Appoints Stephen J. Fanning to its Board
-
The Beauty Health Company (SKIN) PT Raised to $2 at TD Cowen
-
The Beauty Health Company (SKIN) Misses Q3 EPS by 6c ; Offers Guidance
-
The Beauty Health Company (SKIN) Appoints Chief Revenue and Chief Marketing Officers
-
The Beauty Health Company (SKIN) PT Lowered to $1 at Piper Sandler
-
The Beauty Health Company (SKIN) Misses Q2 EPS by 8c ; Offers Guidance
-
The Beauty Health Company (SKIN) PT Lowered to $2 at Canaccord Genuity
-
Here's why beauty is likely to remain one of the highest growth categories

